A new pharmaceutical factory will be built in Kazakhstan with an investment of over 39 billion tenge. It is planned to establish a new pharmaceutical factory in Almaty that will allow expanding the production of drugs, deepen the localization of international developments and create preconditions for the production of pharmaceutical substances within the country. Chairman of the Board of Directors of JSC "Nobel Almaty Pharmaceutical Plant" Svetlana Kiel announced this at the cabinet meeting. The scope of investment in the project exceeds 39 billion tenge. One of the main areas of development is expanding the localization of international medicines. Today, the production of four oncology drugs is domestic in Kazakhstan, they are -. Kadsil, Roche's Herceptin and Freita, and AstraZeneca's Forcig. Also, a contract was signed with Sanofi on the localization of vaccine production. The new plant aims to further deepen the production processes. In the first phase - in the years 2030-2033, it is planned to develop ready-made medical forms, technology transfer and full cycle production. The next period to 2034-2036 is intended to organize the production of active pharmaceutical ingredients, which will allow to gradually reduce the dependence on imported raw materials. The investment agreement stipulates the localization of 40 international off-patent names of drugs, which constitute 68 production positions in 12 therapeutic directions. The focus is on oncology and hematology, which constitute 17 and 7 international off-patent generic names, respectively. The first launch is planned for 2029. In the years 2029-2032, 23 out of 40 names are planned to go into production. It is planned to open new production areas in 2030, which are: rheumatology, immunology and treatment of pulmonary hypertension. In 2032, six biological positions are expected to be activated: five for oncology and one for hematology.

A new pharmaceutical factory will be built in Kazakhstan with an investment of over 39 billion tenge. It is planned to establish a new pharmaceutical factory in Almaty that will allow expanding the production of drugs, deepen the localization of international developments and create preconditions for the production of pharmaceutical substances within the country. Chairman of the Board of Directors of JSC "Nobel Almaty Pharmaceutical Plant" Svetlana Kiel announced this at the cabinet meeting. The scope of investment in the project exceeds 39 billion tenge. One of the main areas of development is expanding the localization of international medicines. Today, the production of four oncology drugs is domestic in Kazakhstan, they are -. Kadsil, Roche's Herceptin and Freita, and AstraZeneca's Forcig. Also, a contract was signed with Sanofi on the localization of vaccine production. The new plant aims to further deepen the production processes. In the first phase - in the years 2030-2033, it is planned to develop ready-made medical forms, technology transfer and full cycle production. The next period to 2034-2036 is intended to organize the production of active pharmaceutical ingredients, which will allow to gradually reduce the dependence on imported raw materials. The investment agreement stipulates the localization of 40 international off-patent names of drugs, which constitute 68 production positions in 12 therapeutic directions. The focus is on oncology and hematology, which constitute 17 and 7 international off-patent generic names, respectively. The first launch is planned for 2029. In the years 2029-2032, 23 out of 40 names are planned to go into production. It is planned to open new production areas in 2030, which are: rheumatology, immunology and treatment of pulmonary hypertension. In 2032, six biological positions are expected to be activated: five for oncology and one for hematology.